American Journal of Cardiovascular Drugs

, Volume 3, Issue 1, pp 77–78

Ezetimibe

A Viewpoint by Tatu A. Miettinen

Authors

  • Tatu A. Miettinen
    • Department of MedicineUniversity of Helsinki
Guest Commentary

DOI: 10.2165/00129784-200303010-00010

Cite this article as:
Miettinen, T.A. Am J Cardiovasc Drugs (2003) 3: 77. doi:10.2165/00129784-200303010-00010
  • 12 Views

Copyright information

© Adis International Limited 2003